Bertie the Brain

Bertis Announces Research Results of AI-based Disease Diagnosis Model in the World’s Largest Academic Event in Proteomics

Retrieved on: 
Thursday, December 8, 2022
Research, Technology, Engineering, Manufacturing, Biotechnology, Health, Data Management, Science, Oncology, Artificial Intelligence, Ovarian cancer, Korean Intellectual Property Office, Multiomics, SAME, Ministry of Food and Drug Safety, Spectrum, Software, MFDS, Diagnosis, Plasma, Korean Ministry of Culture, PASS, Patient, Biomarker, Cancer, Ministry, AND, Mass spectrometry, Research, Precision medicine, NET, Breast cancer, Scientific programming language, Disease, Deep learning, Medicine, AI, Proteome, MOTIE, Guideline, Khidi-Khutor, Multimedia, Marketing, Proteomics, Health, Machine learning, HUPO, Pancreatic cancer, Patent, Algorithm, Medical device, Medical imaging, Food, Bertie the Brain, SAN

Bertis , a proteomics-based precision medicine technology development company (CEOs Dong-young Noh, Seung-man Han), announced research results of AI-based disease diagnosis model, on December 8, 2022, at Human Proteome Organization 2022 (HUPO 2022), the worlds largest academic event in the field of proteomics1.

Key Points: 
  • Bertis , a proteomics-based precision medicine technology development company (CEOs Dong-young Noh, Seung-man Han), announced research results of AI-based disease diagnosis model, on December 8, 2022, at Human Proteome Organization 2022 (HUPO 2022), the worlds largest academic event in the field of proteomics1.
  • According to the results of its research, Bertis developed a diagnosis model that can determine the presence of a disease solely with proteomic mass spectrometry data by applying deep learning-based AI technology.
  • View the full release here: https://www.businesswire.com/news/home/20221208005409/en/
    Eric Y. Kim, Principal Machine Learning Engineer of Bertis Bioscience, is sharing the research results of a deep learning-based disease diagnosis model.
  • Bertis deep learning model uses only the proteomic spectrum to determine the existence of ovarian and pancreatic cancer with over 95% accuracy.

Bertis Establishes U.S. Operations to Bring Novel Proteomics-Based Diagnostics to the U.S. Market

Retrieved on: 
Tuesday, October 11, 2022
Proteomics, LinkedIn, Pancreatic cancer, CLIA, Medicine, Korean Intellectual Property Office, Diagnosis, Machine learning, Korean Ministry of Culture, Patient, Hospital, American Chemical Society, Raffles Medical Group, Research, Disorder, Cancer, Multimedia, Artificial intelligence, Precision medicine, Technology, Cancer Breakthroughs 2020, PASS, Solution, Human body, Biomarker, Raffles, National Cancer Institute, AI, Breast cancer, PMID, American, Ministry of Food and Drug Safety, Protein, Journal, Proteome, Plasma, Ministry, NET, Ovarian cancer, Journal of Proteome Research, View, Pharmaceutical industry, Medical device, Medical imaging, Dentistry, Bertie the Brain, Food

SEOUL, Korea, Oct. 11, 2022 /PRNewswire/ -- Bertis Inc., a South Korean proteomics-based precision medicine technology company, announced today it has established a U.S.-based wholly-owned entity to expand the company's global presence and primarily provide access to the growing U.S. clinical testing market.

Key Points: 
  • The company has successfully commercialized in South Korea MASTOCHECKTM, the world's first proteomics-based breast cancer blood test solution.
  • Bertis has gained a foothold in the Asian market by recently signing a contract with one of Singapore's largest medical groups, Raffles Medical Group, to supply MASTOCHECKTM.
  • Recently, Bertis' research team presented protein biomarkers for early diagnosis of high-grade serous ovarian cancer (HGSOC) with 95% accuracy4.
  • Bertis' capabilities range from cancer, disorder biomarker discovery, low-cost diagnostics manufacturing and analysis services.